Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16090766 | 0.86 | PARG (0.36) | CNR2PGRCTSLCTSSCTSK | |
| SCHEMBL16090775 | 0.81 | PARG (0.37) | CNR2PGRPARG | |
| SCHEMBL16090774 | 0.80 | BRPF1 (0.34) | PGR | |
| SCHEMBL16090776 | 0.78 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL18256193 | 0.69 | CCR2 (0.32) | — | |
| SCHEMBL16030138 | 0.63 | NR1H2 (0.47) | — | |
| SCHEMBL25421605 | 0.63 | DDB1 (0.33) | CNR2PGR | |
| SCHEMBL19301847 | 0.62 | SIGMAR1 (0.39) | PGRGRM2 | |
| SCHEMBL30406392 | 0.62 | FEN1 (0.38) | CNR2PGR | |
| SCHEMBL23755687 | 0.61 | HTR7 (0.41) | CNR2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| WO-2014164543-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | CNR2 3793/4885PGR 4044/4885CTSL 4860/4885 |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | CNR2 3518/4885PGR 3879/4885CTSL 4859/4885 |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | CNR2 3323/4885PGR 3713/4885CTSL 4872/4885 |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | CNR2 3157/4885PGR 3649/4885CTSL 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.